[Concordance Between the Test of the Tuberculin and Interferon Gamma Release Assay-IGRA in Patients with Immune-mediated Inflammatory Diseases]

Overview

Journal Rev Esp Quimioter

Specialty Pharmacology

Date 2019 Sep 17

PMID 31523944

Citations 2

Authors

I Perez Catalan

C Roig Marti

M Gil Fortuno

P Torrent Ramos

P Albiol Vinals

M Carballido Fernandez

R M Larrea

C Ortin Martin

J Uso Blasco

J M Ramos Rincon

Affiliations

Soon will be listed here.

Abstract

Objective: The immunosuppressive therapies in the treatment of the immune-mediated inflammatory diseases (EIMI) predispose individuals to the tuberculosis, so the screening of latent tuberculosis infection (ITL) and the treatment reduces the likelihood of a progression to an active tuberculosis. The aim of the study was to analyze the concordance between the test of the tuberculin (PT) and "Interferon Gamma Release Assay-IGRA" in relation to the type of EIMI and the immunosuppressive treatment (IS).

Methods: Transversal study of patients with EIMI candidates or in treatment IS forwarded to the ITL screening, from April 2017 until May 2018. The outcome variables were PT and IGRA. The explicative variables were: EIMI, IS, age, gender, prior BCG vaccination and tuberculosis risk factors.

Results: A total of 146 patients were analyzed (33[22.6%] vaccinated with BCG, 1 [0.7%] with a pre-diagnosis of tuberculosis, and 22 [15.1%] from an endemic country). Kappa index (k) was 0,338 between PT and IGRA for the whole sample. A lower concordance was found in patients with the Crohn's disease (k=0.125), in the ones treated with corticosteroids (k=0.222), vaccinated with BCG (k=0.122) and in patients from tuberculosis endemic countries (k=0.128).

Conclusions: The concordance between PT and IGRA is affected in patients with EIMI, and to a greater extent to patients with the inflammatory bowel disease, with the corticotherapy, with the BCG vaccination, or in the ones from endemic countries.

Citing Articles

Assessing the Diagnostic Performance of New Commercial Interferon-γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-Analysis.

Ortiz-Brizuela E, Apriani L, Mukherjee T, Lachapelle-Chisholm S, Miedy M, Lan Z Clin Infect Dis. 2023; 76(11):1989-1999.

PMID: 36688489 PMC: 10249994. DOI: 10.1093/cid/ciad030.

Diagnosis for Latent Tuberculosis Infection: New Alternatives.

Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, Torres M Front Immunol. 2020; 11:2006.

PMID: 33013856 PMC: 7511583. DOI: 10.3389/fimmu.2020.02006.

References

Munoz L, Casas S, Juanola X, Bordas X, Martinez C, Santin M . Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study. Clin Infect Dis. 2014; 60(3):349-56. DOI: 10.1093/cid/ciu796. View

Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puechal X . Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis. 2007; 66(12):1610-5. PMC: 2095326. DOI: 10.1136/ard.2007.069799. View

Inanc N, Aydin S, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H . Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2009; 36(12):2675-81. DOI: 10.3899/jrheum.090268. View

Schoepfer A, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L . Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008; 103(11):2799-806. DOI: 10.1111/j.1572-0241.2008.02050.x. View

Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M . Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients. J Infect Chemother. 2011; 17(6):842-8. DOI: 10.1007/s10156-011-0250-1. View

. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This.... Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1376-95. DOI: 10.1164/ajrccm.161.4.16141. View

Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J . Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008; 35(5):776-81. View

Mir Viladrich I, Dauden Tello E, Solano-Lopez G, Lopez Longo F, Taxonera Samso C, Sanchez Martinez P . Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol. 2015; 52(1):36-45. DOI: 10.1016/j.arbres.2015.04.016. View

Santin M, Garcia-Garcia J, Rigau D, Altet N, Anibarro L, Casas I . Executive Summary of the Guidelines for the Use of interferon-gamma Release Assays in the Diagnosis of Tuberculosis Infection. Arch Bronconeumol. 2016; 52(9):477-81. DOI: 10.1016/j.arbres.2016.02.020. View

10.

Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M . Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol. 2009; 20(1):18-23. DOI: 10.1007/s10165-009-0226-5. View

11.

Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J . Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis. 2009; 69(1):181-5. DOI: 10.1136/ard.2008.101857. View

12.

Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N . Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis. 2008; 27(10):907-13. DOI: 10.1007/s10096-008-0519-1. View

13.

Qumseya B, Ananthakrishnan A, Skaros S, Bonner M, Issa M, Zadvornova Y . QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2010; 17(1):77-83. DOI: 10.1002/ibd.21329. View

14.

Chiu H, Hsueh P, Tsai T . Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol. 2010; 164(3):553-9. DOI: 10.1111/j.1365-2133.2010.10137.x. View

15.

Ramos J, Masia M, Rodriguez J, Lopez C, Padilla S, Robledano C . Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med. 2012; 13(3):177-86. DOI: 10.1007/s10238-012-0192-7. View

16.

Keane J, Gershon S, Wise R, Kasznica J, Schwieterman W, Siegel J . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15):1098-104. DOI: 10.1056/NEJMoa011110. View

17.

Wong S, Gao Q, Tsoi K, Wu W, Tam L, Lee N . Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2015; 71(1):64-72. DOI: 10.1136/thoraxjnl-2015-207811. View

18.

Chen D, Shen G, Hsieh T, Hsieh C, Lan J . Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum. 2008; 59(6):800-6. DOI: 10.1002/art.23705. View

19.

Belard E, Semb S, Ruhwald M, Werlinrud A, Soborg B, Jensen F . Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011; 17(11):2340-9. DOI: 10.1002/ibd.21605. View

20.

Gomez-Reino J, Carmona L, Rodriguez Valverde V, Martin Mola E, Montero M . Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48(8):2122-7. DOI: 10.1002/art.11137. View